Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04384029
Other study ID # CCER-2020-00610
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 24, 2020
Est. completion date July 31, 2021

Study information

Verified date October 2021
Source University Hospital, Geneva
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In this study, the investigators propose to analyse the clinical data of all patients admitted in Geneva University Hospitals (HUG) or in a care center in Geneva who are diagnosed with COVID-19. CVD being one of the most important risk factors for developing a severe form of the disease, the investigators will explore the prognosis and clinical outcomes of those patients according to their CVD history as well as newly onset CVD during hospitalization. Moreover, as further evidence is needed on the use of renin-angiotensin-aldosterone system (RAAS) inhibitors for SARS-CoV-2 infected patients, the investigators will study prognosis and outcomes according to the patients' medications. Finally, the investigators propose to evaluate hospital length of stay and cost. The aim, therefore, is to collect information and scientific evidence from patients hospitalized and diagnosed positive for COVID-19, in order to evaluate if previous (or newly onset) CVD may influence outcomes and costs.


Description:

Hypothesis: COVID-19+ hospitalized patients with preexisting CVD or newly onset CVD at time of hospitalization have different clinical outcomes compared to those without CVD and COVID-19+. Objectives: The primary aim of this study is to gather observational data, starting from February 1st 2020 until the end of the pandemic, to compare clinical outcomes COVID+ hospitalized patients at HUG or in a care center in Geneva with pre-existing or newly onset CVD, to COVID+ hospitalized patients at HUG or in a care center in Geneva without pre-existing CVD. The secondary aims of this study are: - To determine the association between COVID-19 disease and CVD, based on: age, previous CV diseases, CV risks factors, CV medications (e.g. ACE Inhibitors or angiotensin II receptor antagonists) - To explore CVD profiles that may influence COVID-19 disease outcomes - To determine the cause of death in CVD patients (either with preexisting CVD or newly diagnosed with CVD) - To understand the vulnerability of the myocardium (new event of either heart failure, acute coronary syndrome, arrhythmia, myocarditis) in patients with COVID-19 disease.


Recruitment information / eligibility

Status Completed
Enrollment 1927
Est. completion date July 31, 2021
Est. primary completion date June 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subject is =18 years of age. - Patient diagnosed SARS-CoV-2 positive at time of hospitalization. - In case of the subject accepting the follow-up at 30 days and 1 year, Signed Patient Informed Consent (PIC) form Exclusion Criteria: - Patients unwilling to provide informed consent for the follow-up.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Covid-19 + patients
all the patients hospitalized in Geneva and SARS-Cov2 positive

Locations

Country Name City State
Switzerland Geneva University Hospital (HUG) Geneva

Sponsors (1)

Lead Sponsor Collaborator
François MACH

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary mobidity discharge To compare morbidity during hospital stay in COVID-19+ patients with or without preexisting CVD. 0 days after hospitalization
Primary mobidity at 30 days To compare morbidity 30 days after hospitalization in COVID-19+ patients with or without preexisting CVD. 30 days after hospitalization
Primary mobidity 1 year after hospitalization To compare morbidity 1 year after hospitalization stay in COVID-19+ patients with or without preexisting CVD. 1 year after hospitalization
Primary mortality discharge To compare mortality during hospital stay in COVID-19+ patients with or without preexisting CVD. 0 days after hospitalization
Primary mortality 30 days after hospitalization To comparemortality30 days after hospital stay in COVID-19+ patients with or without preexisting CVD. 30 days after hospitalization
Primary mortality 1 year after hospitalization To compare mortality 1 year after hospital stay in COVID-19+ patients with or without preexisting CVD. 1 year after hospitalization
Secondary Clinical outcomes according to medication at admission Clinical outcomes according to medication at admission evaluated at hospital discharge 0 days after hospitalization
Secondary Clinical outcomes according to medication at admission Clinical outcomes according to medication at admission evaluated 30 days after hospitalization 30 days after hospitalization
Secondary Clinical outcomes according to medication at admission 1 year after hospitalization 1 year after hospitalization
Secondary Clinical outcomes related to preexisting cardiovascular risk factors at admission Clinical outcomes related to preexisting cardiovascular risk factors at admission evaluated after hospital discharge 0 days after hospitalization
Secondary Clinical outcomes related to preexisting cardiovascular risk factors at admission Clinical outcomes related to preexisting cardiovascular risk factors at admission evaluated 30 days after hospital discharge 30 days after hospitalization
Secondary Clinical outcomes related to preexisting cardiovascular risk factors at admission Clinical outcomes related to preexisting cardiovascular risk factors at admission evaluated 1 year after hospitalization 1 year after hospitalization
Secondary New onset of CVD induced by COVID-19 disease New onset of CVD induced by COVID-19 disease at discharge 0 days after hospitalization
Secondary New onset of CVD induced by COVID-19 disease New onset of CVD induced by COVID-19 disease evaluated 30 days after hospitalization 30 days after hospitalization
Secondary New onset of CVD induced by COVID-19 disease New onset of CVD induced by COVID-19 disease at discharge evaluated 1 year after hospitalization 1 year after hospitalization
Secondary Cost of hospital stay Cost of hospital stay 0 days after hospitalization
Secondary Clinical follow up at 30 days (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis). Clinical follow up at 30 days (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis). 30 days after hospitalization
Secondary Clinical follow up at 1 year (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis). Clinical follow up at 1 year (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis). 1 year after hospitalization
See also
  Status Clinical Trial Phase
Terminated NCT04558125 - Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism Phase 4
Recruiting NCT04410510 - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 Phase 2/Phase 3
Active, not recruiting NCT04420676 - Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection N/A
Completed NCT04419025 - Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease Phase 2
Completed NCT04425317 - Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients N/A
Completed NCT04395911 - Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections N/A
Withdrawn NCT04456426 - Characteristics of Patients With COVID-19 in Meta State, Colombia
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Completed NCT04425720 - Use of Remote Monitoring for COVID-19 Patient N/A
Suspended NCT04385771 - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation N/A
Completed NCT04419610 - RAS and Coagulopathy in COVID19 Early Phase 1
Completed NCT04546581 - Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC) Phase 3
Completed NCT04435327 - Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Terminated NCT04530448 - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Phase 4
Not yet recruiting NCT04524156 - COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2 N/A
Completed NCT04441710 - Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus
Completed NCT04357834 - WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
Not yet recruiting NCT04392427 - New Antiviral Drugs for Treatment of COVID-19 Phase 3
Terminated NCT04614025 - Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19 Phase 2
Completed NCT04402957 - LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) Phase 2